StreetInsider.com News Articles

Form 6-K Can-Fite BioPharma Ltd. For: Sep 02

Wed, 02 Sep 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20260902/27016553.html

Can-Fite reports longer survival in HCC trial than anticipated

Wed, 02 Sep 2026 07:07:41 -0400

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) announced that blinded overall survival observed across the entire patient population in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma (HCC) appears longer than originally anticipated based on the assumptions underlying the study design.

The Phase III study is a randomized, double-blind, placebo-controlled trial evaluating Namodenoson in patients with advanced HCC and underlying Child-Pugh B7 cirrhosis. Patients are randomized 2:1 to receive Namodenoson or placebo, with overall survival as the primary efficacy endpoint.

The company noted that the observed survival reflects the pooled, blinded study population and includes patients receiving

Form 6-K Can-Fite BioPharma Ltd. For: Sep 02

Wed, 02 Sep 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260902/27015541.html

Form F-3 Can-Fite BioPharma Ltd.

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998104.html

Form F-3 Can-Fite BioPharma Ltd.

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998104.html

Form F-3 Can-Fite BioPharma Ltd.

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998104.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 17

Mon, 17 Aug 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26934755.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 17

Mon, 17 Aug 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26934755.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 17

Mon, 17 Aug 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260817/26934755.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 12

Wed, 12 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26908762.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 12

Wed, 12 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26908762.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 12

Wed, 12 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26908762.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 03

Mon, 03 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260803/26853759.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 03

Mon, 03 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260803/26853759.html

Form 6-K Can-Fite BioPharma Ltd. For: Aug 03

Mon, 03 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260803/26853759.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 20

Mon, 20 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26786897.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 20

Mon, 20 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26786897.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 20

Mon, 20 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260720/26786897.html

Can-Fite pancreatic cancer drug data accepted for ESMO 2026 presentation

Mon, 20 Jul 2026 07:00:18 -0400

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) announced that an abstract from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026.

The abstract, titled "Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study," covers a study of oral Namodenoson in patients with advanced pancreatic cancer who had progressed following prior standard therapies. According to the company, the study met its primary safety endpoint and showed survival outcomes along with disease stabilization. One patient

Can-Fite pancreatic cancer drug data accepted for ESMO 2026 presentation

Mon, 20 Jul 2026 07:00:18 -0400

Can-Fite pancreatic cancer drug data accepted for ESMO 2026 presentation

Mon, 20 Jul 2026 07:00:18 -0400

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Ramat Gan, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an abstract highlighting positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC), has been accepted for poster presentation at the European Society

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Mon, 20 Jul 2026 07:00:00 -0400

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months